²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience.

Kratochwil C, Giesel FL, Bruchertseifer F, Mier W, Apostolidis C, Boll R, Murphy K, Haberkorn U, Morgenstern A. · 2014

Read ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. by Kratochwil C, Giesel FL, Bruchertseifer F, Mier W, Apostolidis C, Boll R, Murphy K, Haberkorn U, Morgenstern A. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4525192.txt.

Introduction

C. Kratochwil leads a nine-author team reporting a first-in-human cancer treatment in the European Journal of Nuclear Medicine and Molecular Imaging in 2014. Patients with neuroendocrine tumors had kept growing despite therapy with beta-radiation drugs aimed at a surface receptor. Few options remained for them. The new approach swapped the beta emitter for an alpha emitter, bismuth-213, on the same targeting drug, DOTATOC.

Eight patients were treated, seven through an artery into liver tumors and one through the whole body for marrow spread. Seven had follow-up beyond two years. Scans confirmed the drug bound the tumors, and lasting responses appeared in all treated patients. Side effects on blood, kidneys, and hormone glands were tracked against standard criteria.

Catalog record

CREATORKratochwil C, Giesel FL, Bruchertseifer F, Mier W, Apostolidis C, Boll R, Murphy K, Haberkorn U, Morgenstern A.
YEAR2014
COLLECTIONPAPERS
FORMATTXT
FILE SIZE52 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4525192

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience By C. Kratochwil, F. L. Giesel, F. Bruchertseifer, W. Mier, C. Apostolidis, R. Boll, K. Murphy, U. Haberkorn, A. Morgenstern Published in: European Journal of Nuclear Medicine and Molecular Imaging DOI: 10.1007/s00259-014-2857-9 ABSTRACT Purpose Radiopeptide therapy using a somatostatin analogue labelled with a beta emitter such as 90Y/177Lu-DOTATOC is a new therapeutic option in neuroendocrine cancer. Alternative treatments for patients with refractory disease are rare. Here we report the first-in-human experience with 213Bi-DOTATOC targeted alpha therapy (TAT) in patients pretreated with beta emitters. Methods Seven patients with progressive advanced neuroendocrine liver metastases refractory to treatment with 90Y/177Lu-DOTATOC were treated with an intraarterial infusion of 213Bi-DOTATOC, and one patient with bone marrow carcinosis was treated with a systemic infusion of 213Bi-DOTATOC. Haematological, kidney and endocrine toxicities were assessed according to CTCAE criteria. Radiological response was assessed with contrast-enhanced MRI and 68Ga-DOTATOC-PET/CT. More than 2 years of follow-up were available in seven patients. Results The biodistribution of 213Bi-DOTATOC was evaluable with 440 keV gamma emission scans, and demonstrated specific tumour binding. Enduring responses were observed in all treated patients. Chronic kidney toxicity was moderate. Acute haematotoxicity was even less pronounced than with the preceding beta therapies. Conclusion TAT can induce remission of tumours refractory to beta radiation with favourable acute and mid-term toxicity at therapeutic effective doses. Electronic supplementary material The online version of this article (doi:10.1007/s00259-014-2857-9) contains supplementary material, which is available to authorized users. INTRODUCTION Well-differentiated neuroendocrine tumours (NETs) demonstrate modest responses to conventional chemotherapy due to their slow proliferation rate [1]. However, the expression of somatostatin receptors by NET enables targeting with high-affinity peptides. When these octreotide analogue peptides are labelled with beta emitters such as 90Y [2] or 177Lu [3] promising anti-tumour effects have been observed. Recently, it has also been demonstrated that an improved tumour to nontumour uptake of radiolabelled DOTATOC is achieved after intraarterial administration in liver metastatic NET patients [4, 5]. However, patients with recurrences are usually refractory to further treatment with beta radiation therapy. Alpha radiation is characterized by high linear energy transfer causing production of 2,000 – 7,000 ion pairs per micrometre, leading to clustered double-strand DNA breaks resulting in rapid cell death from even a single exposure to a few alpha particles. The short range of alpha particles (50 – 100 μm, i.e. about two or three cell diameters) limits the effective range of treatment but also limits damage to untargeted tissue. In contrast, beta-emitting radionuclides result in fewer than 20 ion pairs per micrometre and commonly cause only single-strand DNA breaks with less lethality and more spillover effects caused by “crossfire” (Fig. 1). It has already been demonstrated that the alpha emitter 213Bi is able to overcome radioresistance to beta emitters in vitro [6]. The alpha emitters 225Ac and 213Bi used to label the somatostatin analogue DOTATOC have demonstrated already promising antitumour effects with a favourable therapeutic range in animal studies [7, 8]. Therefore, it seemed reasonable that peptide targeted alpha therapy (TAT) with 213Bi-DOTATOC delivered directly to metastases via intraarterial administration might offer effective therapy to NET patients who have acquired resistance to other therapies.Fig. 1Comparison of alpha and beta emitters. a, c After binding of the radionuclide-labelled octreotide analogue DOTATOC to the somatostatin receptor subtype-2 (SSR2), which is overexpressed in NETs, the emitted alpha particle causes high-density ionization effects, resulting mainly in double-strand DNA breaks. In contrast, the beta particles emitted by established radiopharmaceuticals mainly cause repairable single-strand DNA damage. b, d The tissue range of alpha emitters (about 80 μm) is approximately two cell diameters. The mean tissue range of the beta emitter 90Y (3 mm) is approximately 75 cell diameters. Thus, alpha emitters result in less “cross-fire” radiation to surrounding normal tissue Here we report the first-in-human experience with 213Bi-DOTATOC TAT in patients refractory to nonradioactive octreotide and tandem therapy [9] with 90Y/177Lu-DOTATOC. MATERIALS AND METHODS Patients This was a retrospective study of patients with differentiated neuroendocrine tumours. The diagnosis was confirmed histologically. These patients were not surgical candidates. Systemic standard therapies such as chemotherapy in high-grade or nonradioactive octreotide in low-grade tumours had previously failed to stop tumour growth. Pretreatment also included innovative peptide receptor radiation therapy (PRRT) with octreotide analogues tagged with a beta emitter. When patients showed progression with that treatment (new lesions on PET or progression on CT >30 % within the previous 2 – 6 months) TAT was offered as an alternative therapy. Seven consecutive patients with prognosis-affecting liver metastases arising from a pulmonary (one patient), pancreatic (four patients), enteric (one patient) or unknown primary (one patient) received intraarterial administration into the common hepatic artery between November 2010 and October 2011, and one patient with bone marrow carcinosis arising from neuroendocrine prostate cancer was treated systemically (Table 1, Supplementary Fig. 1). A positive tumour somatostatin receptor expression was validated by 68Ga-DOTATOC PET/CT. After the patients had given written informed consent, salvage therapies (compassionate use) were administered in accordance with the principles of the Helsinki Declaration (paragraph 37 “Unproven Interventions in Clinical Practice”) and our national regulations. The retrospective analyses of our observations were done with the approval of our ethics committee.Table 1Patient characteristicsPatientGenderHistologyPretreatmentPRRT with beta emitters (GBq)Duration of tumour control under PRRT with beta emitters (months) 213Bi administrationResponse (RECIST)Course of follow-up 90Y 177LuCyclesCumulative activity (GBq)Highest single activity (GBq)Follow-up duration (months)Outcome1mCarcinoid (Ki-67 2 %)Surgery (primary), radiotherapy (bone), OCT, Str/5-FU20837516.07.6PR (−32 %)17PFS2fP-NET (Ki-67 2 %)OCT162438519.57.9n.a. (disseminated)30PFS3fAtypical pulmonary carcinoid, grade III (Ki-67 25 %)Pl/ETO846519.37.4SD34PFS4mP-NET (Ki-67 5 %)Pl, OCT1046420.86.8SD12PFS5fP-NET (Ki-67 15 %)OCT181419413.35.9CR>28 (ongoing)CR6mNeuroendocrine CUP (Ki-67 2 %)OCT, Siro13211520.66.7SD31 (ongoing)PFS7fP-NET (Ki-67 10 %)OCT221221213.710.5PR (−35 %)15PFS8mNeuroendocrine prostate cancer (Ki-67 10 %)OCT6123413.33.3n.a. (bone marrow carcinosis)6 (ongoing)PFS PRRT peptide receptor radionuclide therapy, P-NET pancreatic neuroendocrine tumor, CUP cancer of unknown primary, OCT octreotide, Str streptozotocin, 5-FU 5-fluorouracil, PI platin, ETO etoposide, Siro sirolimus CR complete response, PR partial response, SD stable disease, n.a. not available, PFS progression-free survival Peptide, radionuclides and radiolabelling DOTATOC (DOTA0-Phe1-Tyr3) octreotide was synthesized as described by Otte et al. [10]. 225Ac was produced by radiochemical extraction from 229Th as described by Apostolidis et al. and Boll et al. [11, 12] and loaded on a 225Ac/213Bi radionuclide generator comprising AG MP-50 cation exchange resin (Bio-Rad) [13]. 213Bi was eluted as BiI4−/BiI52− ion at intervals of 2 – 3 h using 1.4 ml 0.1 M HCl/0.1 M NaI. The eluate was added to a microwave vial containing 350 μl 2 M TRIS buffer, 100 μl 20 % ascorbic acid and 15 μl of 2 mg/ml DOTATOC solution. The reaction mixture was heated to 95 °C for 5 min using a microwave synthesizer (Biotage® Initiator) and subsequently cooled to <50 °C using pressurized air. Quality control was performed by instant thin-layer chromatography (ITLC-SG; Pall Life Sciences) with 0.05 M citric acid, pH 5, as solvent. Under these conditions, unbound 213Bi moves with the solvent front (Rf = 1), while 213Bi-DOTATOC remains on the bottom of the strip (Rf = 0). Radiochemical purity was determined by measuring the activity of the 440 keV gamma emission of 213Bi on the upper and lower part of the ITLC strip in an automated gamma counter (Berthold) using an energy window of 400 – 500 keV. Radiochemical purity

Read the complete text